Login to Your Account

Pozen Receives Not-Approvable Letter For MT 300; Stock Suffers

By Kim Coghill

Tuesday, October 21, 2003
Pozen Inc.'s stock Monday took a major hit on news that the FDA rejected the firm's injectable migraine candidate because it failed to achieve statistical significance on secondary endpoints at the two-hour measuring point. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription